Atara Biotherapeutics (NASDAQ:ATRA) CEO Anhco Nguyen Sells 5,241 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 5,241 shares of Atara Biotherapeutics stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $9.13, for a total value of $47,850.33. Following the transaction, the chief executive officer owned 137,837 shares of the company’s stock, valued at $1,258,451.81. This represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atara Biotherapeutics Stock Performance

NASDAQ:ATRA traded up $0.04 during mid-day trading on Wednesday, hitting $9.45. 80,398 shares of the stock were exchanged, compared to its average volume of 1,179,400. The stock has a market capitalization of $85.14 million, a price-to-earnings ratio of -14.10 and a beta of -0.30. The firm’s 50-day simple moving average is $5.92 and its 200 day simple moving average is $9.00. Atara Biotherapeutics, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $19.15.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $2.90 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%. On average, analysts predict that Atara Biotherapeutics, Inc. will post 0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. bought a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at $31,000. Dimensional Fund Advisors LP bought a new position in shares of Atara Biotherapeutics in the 4th quarter valued at $181,000. Walleye Capital LLC bought a new position in shares of Atara Biotherapeutics in the 4th quarter valued at $220,000. Quadrature Capital Ltd increased its stake in shares of Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 3,779 shares during the last quarter. Finally, GSA Capital Partners LLP increased its stake in shares of Atara Biotherapeutics by 33.8% in the 3rd quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 6,622 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Key Stories Impacting Atara Biotherapeutics

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Freedom Capital upgraded Atara Biotherapeutics from “strong sell” to “hold,” which can support sentiment by signaling less bearish expectations for the company. Read More
• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Levi & Korsinsky, Pomerantz, Bronstein, and The Gross Law Firm, announced or renewed notices about a class-action lawsuit and the May 22, 2026 deadline for investors to seek lead-plaintiff status. These updates do not change fundamentals directly, but they keep legal risk and investor uncertainty in focus. Article Title
• Neutral Sentiment: The repeated class-action announcements allege securities-law violations and seek damages for investors who bought Atara shares during the specified class period, reinforcing an existing legal overhang rather than introducing a new operational development. Article Title

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Canaccord Genuity Group set a $13.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Friday, May 8th. Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Freedom Capital raised Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Friday, March 27th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.50.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.